Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA.
about
A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: ResuSafety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting.A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases.
P2860
Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Pharmacokinetic and Pharmacody ...... Trials: SUMMACTA and BREVACTA.
@en
Pharmacokinetic and Pharmacody ...... Trials: SUMMACTA and BREVACTA.
@nl
type
label
Pharmacokinetic and Pharmacody ...... Trials: SUMMACTA and BREVACTA.
@en
Pharmacokinetic and Pharmacody ...... Trials: SUMMACTA and BREVACTA.
@nl
prefLabel
Pharmacokinetic and Pharmacody ...... Trials: SUMMACTA and BREVACTA.
@en
Pharmacokinetic and Pharmacody ...... Trials: SUMMACTA and BREVACTA.
@nl
P2093
P2860
P356
P1476
Pharmacokinetic and Pharmacody ...... Trials: SUMMACTA and BREVACTA.
@en
P2093
Alan Kivitz
Hisham Abdallah
Lucy Rowell
Scott Fettner
Wendy Douglass
Xiaoping Zhang
P2860
P304
P356
10.1002/JCPH.826
P577
2016-09-07T00:00:00Z